Market Closed -
Nasdaq
01:30:00 16/05/2024 am IST
5-day change
1st Jan Change
13.34
USD
+0.76%
+4.55%
+41.76%
This article is reserved for members
Not a member ?
Free registration
JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating
07/05
MT
Transcript : Enanta Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 06, 2024
07/05
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M
07/05
MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
07/05
CI
Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer
30/04
CI
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating
09/02
MT
Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024
08/02
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M
08/02
MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
08/02
CI
Transcript : Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM
10/01
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024
27/12
CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from NASDAQ Biotechnology Index
15/12
CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
24/11
MT
Sector Update: Health Care
24/11
MT
Enanta Pharmaceuticals Files $150 Million Mixed Shelf
24/11
MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating
22/11
MT
HC Wainwright Cuts Enanta Pharmaceuticals' Price Target to $28 From $30, Maintains Buy Rating
21/11
MT
Transcript : Enanta Pharmaceuticals, Inc., Q4 2023 Earnings Call, Nov 20, 2023
21/11
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q4 Revenue $18.9M, vs. Street Est of $17.5M
21/11
MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
21/11
CI
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023
21/11
CI
HC Wainwright Adjusts Enanta Pharmaceuticals Price Target to $30 From $48, Maintains Buy Rating
23/23/23
MT
Transcript : Enanta Pharmaceuticals, Inc. - Special Call
20/23/20
Enanta Pharmaceuticals Receives Speculative Risk Qualifier on Sector Perform Rating From RBC, Price Target Cut to $15 From $25
02/23/02
MT
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P Biotechnology Select Industry Index
18/23/18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).
More about the company
Last Close Price
13.34
USD
Average target price
19.75
USD
Spread / Average Target
+48.05%
Consensus
1st Jan change
Capi.
+41.76% 28Cr +29.77% 4.95TCr +1.00% 4.26TCr +49.45% 4.25TCr -5.26% 2.91TCr +13.68% 2.66TCr -22.99% 1.86TCr +8.22% 1.32TCr +32.41% 1.25TCr +24.01% 1.21TCr
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**